Sort
50,496 grants matching “lung cancer”
Unraveling the molecular mechanisms of impaired central tolerance in COPA syndrome
$629,882Anthony Shum · University Of California, San Francisco · R01 · FY2025 · AI
Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
$629,824Jacob Gardinier Scott · Cleveland Clinic Lerner Com-Cwru · R37 · FY2021 · CA
Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.
$629,729Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2025 · EB
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer
$629,612Kwok Kin Wong · New York University School Of Medicine · U01 · FY2020 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2019 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2016 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2017 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2018 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2020 · CA
Proteolytic disregulation of the S326C mutant OGG1 DNA repair enzyme
$629,545Michele K Evans · National Institute On Aging · ZIA · FY2009 · AG
Influence of germline mutations on susceptibility to environmental carcinogens
$629,518Michele Carbone · University Of Hawaii At Manoa · R01 · FY2020 · ES
Phenotypic marker-guided development of selective antimetastasis therapeutic leads
$629,518Sui Huang · Northwestern University At Chicago · R01 · FY2023 · CA
Molecular origins and impact of APOBEC3 mutagenesis in cancer
$629,354John Maciejowski · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Focal Adhesion Kinase inhibition for dual targeting of osteosarcoma cells and the tumor microenvironment to prevent metastasis
$629,341Daniel Patrick Regan · Colorado State University · R37 · FY2025 · CA
CB: Administration, Evaluation, and Planning
$629,237Bruce D Johnson · Dana-Farber Cancer Inst · P50 · FY2010 · CA
Mechanisms of Transition Metal-Induced Carcinogenesis
$629,198Kazimierz S Kasprzak · Basic Sciences · Z01 · FY2007 · CA
Intervention of Pancreatic Oncogenic Pathways with Dietary Tocotrienol
$629,096Mokenge P. Malafa · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2011 · CA
Phenotypic variability within isogenic population of lymphocytes
$629,064Grãgoire Altan-Bonnet · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Structural and molecular determinants of protein phosphatase 2A function in lung cancer
$629,043Goutham Narla · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
The Role of TIMPs in Cell Growth and Differentiation: Tumor Angiogenesis
$628,972William Stetler-Stevenson · Division Of Clinical Sciences - Nci · ZIA · FY2013 · CA
MID ATLANTIC PROSTATE CANCER BANK
$628,670George Washington University · U01 · FY2004 · CA
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
$628,649Scarlett L Gomez · University Of California, San Francisco · R01 · FY2024 · MD
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
$628,641Paul K Paik · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
O-Glycosylation of Epidermal Growth Factor-like Motifs
$628,633Robert S. Haltiwanger · State University New York Stony Brook · R01 · FY2014 · GM
Evaluating Lung Cancer Screening Patterns and Outcomes through a North Carolina Registry
$628,514Louise Henderson · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA